Brookfield and CDPQ Acquire Antylia Scientific in $1.34 Billion Transaction



Elizabeth A. Cooper Elizabeth A. Cooper
Keegan T. Lopez Keegan T. Lopez
Quinn Cronan Quinn Cronan
Adam Hitti Adam Hitti
Brian M. Steinhardt Brian M. Steinhardt
+17

The Firm represented funds affiliated with Brookfield Asset Management in the recently completed acquisition of Antylia Scientific (“Antylia”) in an all-cash transaction valued at approximately $1.34 billion.

Antylia is a diversified life science tools business with a portfolio of products serving the pharma, biopharma, healthcare and environmental markets. Its life sciences portfolio includes well-recognized brands such as Environmental Express, Traceable, SPEX, ZeptoMetrix and Cole-Parmer Essentials.

Brookfield Asset Management is a leading global alternative asset manager with a 120-year history and operations across a broad portfolio of real estate, infrastructure, renewable power, private equity and credit assets.

The Simpson Thacher team includes Elizabeth Cooper, Keegan Lopez, Quinn Cronan, Richard Kenny and Adam Hitti (M&A); Brian Steinhardt, Dorothy Hector, Gordon Lee, Sungjoo Ahn and Sally Jo (Credit); Gregory Grogan, Harry Hudesman and Guanxiong Xu (Executive Compensation and Employee Benefits); Russell Light, Adam Arikat, Tova Pfeffer and Jiha Min (Tax); Lori Lesser and Christine Song (Intellectual Property); Krista McManus and Helene Snyder (Real Estate); and Vanessa Burrows, Jacob Madden and Rebecca Rose (Healthcare).